Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378976 | 1.00 | L3MBTL1 (0.51) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL26672944 | 0.90 | HTR6 (0.50) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL23218891 | 0.90 | HTR6 (0.55) | L3MBTL1HTR6EPHX1PDE10ACCNB2 | |
| SCHEMBL29591721 | 0.90 | HTR6 (0.55) | L3MBTL1HTR6EPHX1PDE10ACCNB2 | |
| SCHEMBL16727042 | 0.89 | L3MBTL1 (0.47) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL22919485 | 0.86 | L3MBTL1 (0.55) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL29352824 | 0.85 | L3MBTL1 (0.45) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL29077852 | 0.85 | HTR6 (0.48) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL15777230 | 0.85 | L3MBTL1 (0.45) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL26683954 | 0.85 | L3MBTL1 (0.56) | L3MBTL1HTR6EPHX1PDE10AADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230115176-A1 | Complement Modulators and Related Methods | RA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-3947352-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2020205501-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-7964649-B2 | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090253760-A1 | HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253760-A1 | HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY | S1PR1, S1PR3, S1PR2 | L3MBTL1 2587/4885HTR6 452/4885EPHX1 1872/4885 |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | L3MBTL1 3162/4885HTR6 4613/4885EPHX1 1101/4885 |
| US-20230115176-A1 | Complement Modulators and Related Methods | C5, C9, C1QBP | L3MBTL1 2398/4885HTR6 2589/4885EPHX1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.